About Us | Contact

Dr. Fredric Jaffe Investigator

Pulmonary Disease NPI1043234008
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$380.34
from 10 payments in the last 6 years

Total Cash or Cash Equivalent

$226.96
from 8 payments in the last 6 years

Total In-kind Items & Services

$153.38
from 2 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
02/03/2021 General (Non-Research) Cash or cash equivalent Food and Beverage $18.60 Details
Payment from HARMONY BIOSCIENCES LLC
Payment Record ID 853075499
09/02/2021 General (Non-Research) In-kind items and services Food and Beverage $27.23 Details
Payment from Actelion Pharmaceuticals US, Inc.
Payment Record ID 788962773
10/02/2020 General (Non-Research) Cash or cash equivalent Food and Beverage $26.01 Details
Payment from Harmony Biosciences LLC
Payment Record ID 750466441
10/02/2020 General (Non-Research) Cash or cash equivalent Food and Beverage $26.01 Details
Payment from Harmony Biosciences LLC
Payment Record ID 750466435
01/03/2017 Research Cash or cash equivalent $6.30 Details
Payment from GlaxoSmithKline, LLC.
Paymment Research Study A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin GSK1325756 co administered with a standard of care antiviral oseltamivir , in the treatment of adults hospitalized with influenza
Payment Record ID 478926253
01/03/2017 Research Cash or cash equivalent $22.80 Details
Payment from GlaxoSmithKline, LLC.
Paymment Research Study A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin GSK1325756 co administered with a standard of care antiviral oseltamivir , in the treatment of adults hospitalized with influenza
Payment Record ID 478926249
01/03/2017 Research Cash or cash equivalent $24.89 Details
Payment from GlaxoSmithKline, LLC.
Paymment Research Study A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin GSK1325756 co administered with a standard of care antiviral oseltamivir , in the treatment of adults hospitalized with influenza
Payment Record ID 478926245
01/03/2017 Research Cash or cash equivalent $24.50 Details
Payment from GlaxoSmithKline, LLC.
Paymment Research Study A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin GSK1325756 co administered with a standard of care antiviral oseltamivir , in the treatment of adults hospitalized with influenza
Payment Record ID 478926241
01/03/2017 Research Cash or cash equivalent $77.85 Details
Payment from GlaxoSmithKline, LLC.
Paymment Research Study A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin GSK1325756 co administered with a standard of care antiviral oseltamivir , in the treatment of adults hospitalized with influenza
Payment Record ID 478926237
12/28/2016 General (Non-Research) In-kind items and services Travel and Lodging $126.15 Details
Payment from Boston Scientific Corporation
Payment Record ID 420818609
;